In recent trading session, Moleculin Biotech Inc (NASDAQ:MBRX) saw 0.7 million shares changing hands at last check today with its beta currently measuring 1.93. Company’s recent per share price level of $1.26 trading at -$0.14 or -9.64% at last check today assigns it a market valuation of $5.26M. That most recent trading price of MBRX’s stock is at a discount of -721.43% from its 52-week high price of $10.35 and is indicating a premium of 68.25% from its 52-week low price of $0.40.

Moleculin Biotech Inc (NASDAQ:MBRX) trade information

Upright in the red during last session for losing -9.64%, in the last five days MBRX remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $1.26 price level, adding 54.68% to its value on the day. Moleculin Biotech Inc’s shares saw a change of -25.59% in year-to-date performance and have moved -0.39% in past 5-day. Moleculin Biotech Inc (NASDAQ:MBRX) showed a performance of -27.71% in past 30-days.

Moleculin Biotech Inc (MBRX) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 18.25% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 49.80% while estimates for its earnings growth in next 5 years are of 36.38%.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 42.47 shares of worth $54146.0 or 1.02% of the total outstanding shares. The later fund manager was in possession of 30.31 shares on Sep 30, 2024, making its stake of worth around $38650.0 in the company or a holder of 0.73% of company’s stock.